COVID-19 and rheumatic diseases: what factors may affect odds of hospitalization?
FDA joins multi-stakeholder effort to leverage real-world data in COVID-19 diagnostic testing space
[UPDATE] FDA allows expanded use of certain health monitoring devices, to limit in-person patient–provider contact during the COVID-19 outbreak
COVID-19: side effects of healthcare’s digitalization in England – harnessing the positives and mitigating the negatives
Patient-provided information for improving real-world evidence: an interview with Elisabeth Oehrlein
Look behind the lecture: the relevance of registry and real-world data throughout a product’s lifecycle
Editor’s highlights from the Journal of Comparative Effectiveness Research – May 2020
Peek behind the paper: costs, exacerbations and pneumonia after initiating combination tiotropium and olodaterol versus triple therapy for COPD
Comparative effectiveness research, Decision science, Cardiopulmonary and vascular, Health economics, Medical devices, pharmaceuticals and vaccines, Outcomes research
ISPOR 2020: do we have sufficient health economics data for digital therapeutics? Economic evaluation abstract highlights
ISPOR 2020: do managed entry agreements for ATMPs exist in Germany? Curative and genetic therapies abstract highlights
ISPOR 2020: how may we enable faster access to multi-indication orphan products? Rare disease and orphan drug abstract highlights
Events, ISPOR, Health technology assessment, Medical devices, pharmaceuticals and vaccines, Methodology, Real-world evidence, Stakeholder engagement
Peek behind the paper: is high-dose baclofen use associated with increased risk of encephalopathy in individuals with chronic kidney disease?
Past medical history of pneumonitis linked with increased risk of cancer treatment-associated pneumonitis